Acquiring Company
Consortium of Indian investors
Acquired Company
Diatron MI
India
GermanyBiotechnologyHealth CareBiotechnologyHealth CareDescription
STRATEC SE signed an agreement on October 30, 2026 to sell its subsidiary Diatron MI to a consortium of Indian investors for a fixed price of € 10.0 million plus agreed earn-out payments. The sale covers all Diatron hematology and clinical chemistry products, while the OEM molecular and immunodiagnostics business stays with STRATEC. Closing is expected in the fourth quarter of 2026, and STRATEC will record € 44.1 million in impairments and amend its 2026 guidance.
Who to call at Consortium of Indian investors, and when
When Consortium of Indian investors changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Consortium of Indian investors raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Consortium of Indian investors, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Consortium of Indian investors. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Consortium of Indian investors makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Diatron MI?
Diatron MI was acquired by Consortium of Indian investors, based in India. The deal was reported on October 30, 2026. A consortium of Indian investors that has agreed to acquire Diatron MI, a subsidiary of STRATEC SE, in a sale of hematology and clinical chemistry products. Consortium of Indian investors is privately held and operates in Biotechnology.
When did Consortium of Indian investors acquire Diatron MI?
Consortium of Indian investors's acquisition of Diatron MI was reported on October 30, 2026. STRATEC SE signed an agreement on October 30, 2026 to sell its subsidiary Diatron MI to a consortium of Indian investors for a fixed price of € 10.0 million plus agreed earn-out payments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Diatron MI do?
Diatron MI is a subsidiary of STRATEC SE offering hematology and clinical chemistry products. Its loss-making business is being sold, while its OEM business in molecular and immunodiagnostics was carved out before the sale and remains with STRATEC. It is privately held, operating in Biotechnology, and is based in Germany.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.